Barclays Lowers Certara (NASDAQ:CERT) Price Target to $8.00

Certara (NASDAQ:CERT) had its price target decreased by research analysts at Barclays from $13.00 to $8.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price objective would suggest a potential upside of 12.99% from the company’s previous close.

Several other brokerages have also weighed in on CERT. Morgan Stanley cut their price objective on shares of Certara from $16.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, December 18th. TD Cowen reiterated a “buy” rating on shares of Certara in a research report on Thursday. KeyCorp cut their price target on Certara from $13.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, January 8th. Craig Hallum cut Certara from a “buy” rating to a “hold” rating and set a $10.00 price objective for the company. in a research note on Friday. Finally, BMO Capital Markets started coverage on Certara in a research note on Thursday, November 13th. They issued a “market perform” rating and a $9.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $11.10.

Certara Price Performance

Certara stock opened at $7.08 on Friday. The business’s 50-day simple moving average is $8.36 and its 200 day simple moving average is $9.89. The company has a quick ratio of 2.09, a current ratio of 2.09 and a debt-to-equity ratio of 0.27. The stock has a market cap of $1.13 billion, a price-to-earnings ratio of -708.00 and a beta of 1.47. Certara has a 12-month low of $6.04 and a 12-month high of $15.38.

Certara (NASDAQ:CERT) last released its earnings results on Thursday, February 26th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). The business had revenue of $103.65 million for the quarter, compared to analyst estimates of $103.23 million. Certara had a negative net margin of 0.38% and a positive return on equity of 4.19%. The business’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.15 earnings per share. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. As a group, research analysts anticipate that Certara will post 0.28 earnings per share for the current year.

Hedge Funds Weigh In On Certara

Several hedge funds and other institutional investors have recently made changes to their positions in CERT. Associated Banc Corp boosted its stake in shares of Certara by 9.7% in the 3rd quarter. Associated Banc Corp now owns 11,920 shares of the company’s stock valued at $146,000 after purchasing an additional 1,051 shares in the last quarter. Police & Firemen s Retirement System of New Jersey raised its position in shares of Certara by 2.5% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 45,745 shares of the company’s stock worth $535,000 after acquiring an additional 1,136 shares during the last quarter. Versant Capital Management Inc raised its holdings in Certara by 66.7% during the 3rd quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock worth $35,000 after purchasing an additional 1,153 shares during the last quarter. Osaic Holdings Inc. raised its position in shares of Certara by 50.7% in the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after acquiring an additional 1,175 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd lifted its position in shares of Certara by 22.5% during the 2nd quarter. ANTIPODES PARTNERS Ltd now owns 6,665 shares of the company’s stock valued at $78,000 after acquiring an additional 1,223 shares during the period. 73.96% of the stock is currently owned by institutional investors and hedge funds.

More Certara News

Here are the key news stories impacting Certara this week:

• Positive Sentiment: FY‑2025 results showed 9% revenue growth to $418.8M, adjusted EBITDA up 10% to $134.5M, and Q4 software revenue +10% — evidence of recovering commercial momentum in the higher‑margin software business. Certara Reports Fourth Quarter 2025 Financial Results
• Positive Sentiment: New CEO Jon Resnick is executing an operational overhaul with plans for sharper strategic focus and ~ $10M of cost avoidance — a management change investors often view as constructive for execution and long‑term growth. CEO signals operational overhaul
• Positive Sentiment: Barclays maintained an Overweight stance on CERT (despite lowering its price target), indicating some sell‑side support for the name even after recent guidance/earnings. Barclays price target change
• Neutral Sentiment: Management will participate in upcoming investor conferences — a chance to press the case for the turnaround and provide more color to investors. Investor conference participation
• Neutral Sentiment: Broker and media earnings breakdowns are circulating (useful for detail on items behind adjusted metrics and bookings vs. revenue). Earnings breakdown
• Negative Sentiment: GAAP and adjusted metrics disappointed in places: Q4 adjusted diluted EPS of $0.09 (down vs. prior year) and a GAAP net loss; management guided FY‑2026 revenue of only 0–4% (and set revenue range below Street expectations), which pressured near‑term growth expectations. Guidance and Q4 results
• Negative Sentiment: Craig Hallum downgraded CERT from Buy to Hold, reflecting analyst caution after the quarter and guidance; such downgrades can increase selling pressure. Analyst downgrade (Craig Hallum)

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.